New Data on HRQOL for Patients With Hepatocellular Carcinoma From the KEYNOTE-240 Trial
Analysis of a cohort from the KEYNOTE-240 trial showed that health-related quality of life for patients with HCC was similar across the 2 arms of the study.
Hepatocellular Carcinoma
Microwave Ablation Compared With radiofrequency Ablation for Treatment of Hepatocellular Carcinoma and Liver Metastases: A Systematic Review and Meta-analysis
[OncoTargets and Therapy] This systematic review and meta-analysis compared MWA and RFA in the treatment of minimally invasive liver cancer. Local tumor progression, technique efficacy, OS, DFS, intrahepatic de novo lesions, extrahepatic metastases, length of stay, and complications were analyzed.
Status of, and Strategies for Improving, Adherence to HCC Screening and Surveillance
[Journal of Hepatocellular Carcinoma] Although prognosis is poor for patients with hepatocellular carcinoma (HCC), especially those with cirrhosis, a prolonged subclinical growth period offers a window of time for curative treatment. In this review, researchers discuss the current status of screening, and what can be done to improve its potential.
Intermediate Stage Hepatocellular Carcinoma: A Summary Review
[Journal of Hepatocellular Carcinoma]
Keytruda Plus Lenvima Combo Gets Breakthrough Status for Hepatocellular Carcinoma
The Breakthrough Therapy designation was based on updated interim results from the multicenter, open-label, phase 1b KEYNOTE-524/Study 116 trial .
Development and Validation of a Prognostic Score Predicting Recurrence in Resected Combined Hepatocellular Cholangiocarcinoma
[Cancer Management and Research] The aim of this study was to establish a prognostic estimation of CHCs after resection (PECAR) score predicting recurrence on the basis of the clinicopathological data.
Cyramza Approved to Treat Hepatocellular Carcinoma
The FDA has approved Cyramza (ramucirumab; Lilly) for use as a single agent in the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of ≥400ng/mL and have been treated with sorafenib.
NHS, HPFS Show Regular Aspirin Use Reduced Hepatocellular Carcinoma Risk
An analysis of results from the NHS and the HPFS showed that regular use of aspirin — standard-dose 325-mg tablets — reduced hepacellular carcinoma in a dose-dependent manner.
Hepatocellular Cancer Pain: Impact and Management Challenges
[Journal of Hepatocellular Carcinoma] A review of the manifestations, treatments, and challenges associated with hepatocellular cancer pain.
Decreased Hepatocellular Carcinoma Tumor Burden With the Achievement of Hepatitis C Virus Sustained Virologic Response: Unlocking the Potential of T-cell-mediated Immunosurveillance
[Journal of Hepatocellular Carcinoma] In this case series, the authors present procedure and treatment specifics for 2 patients with HCV who developed HCC, and discuss the potential role of DAA therapy and immunosurveillance.
